Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 11, 2013, Pages 1781-1783

  Zanotti Fregonara, Paolo ^a   Lammertsma, Adriaan A ^b   Innis, Robert B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; FLUORINE 18; TRACER;

DOSE RESPONSE; DOSIMETRY; DRUG APPROVAL; FEASIBILITY STUDY; FIRST IN HUMAN STUDY; FOOD AND DRUG ADMINISTRATION; HALF LIFE TIME; HAPLORHINI; HUMAN; HYDRATION; INFORMED CONSENT; KINETICS; LETTER; LIQUID CHROMATOGRAPHY; MEDLINE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; RADIATION SAFETY; WHOLE BODY SCINTISCANNING;

FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 84885428372     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2512-x     Document Type: Letter

References (20)

1. Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of (11)C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544-7.
2. van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA. Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2012;39:305-14.
3. Sakata M, Oda K, Toyohara J, Ishii K, Nariai T, Ishiwata K. Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med. 2013;27:285-96.
4. Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies. Nucl Med Biol. 2005;32:869-74.
5. Bottlaender M, Valette H, Roumenov D, Dolle F, Coulon C, Ottaviani M, et al. Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med. 2003;44:596-601.
6. Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, et al. 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003;17:1331-3.
7. Adler L, Wolodzko J, Stabin M, McNelis T, Gammage L, Joshi A. Radiation dosimetry of F18-AV-45 measured by PET/CT in humans. J Nucl Med. 2008;49 Suppl 1:283.
8. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Nucl Med Biol. 2010;37:497-508.
9. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913-20.
10. Giussani A, Janzen T, Uusijarvi-Lizana H, Tavola F, Zankl M, Sydoff M, et al. A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med. 2012;53:985-93.
11. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43:92-6.
12. International Commission on Radiological Protection (ICRP). ICRP Publication 106: radiation dose to patients from radiopharmaceuticals - addendum 3 to ICRP publication 53. Ann ICRP. 2008;38 (1-2).
13. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565-74.
14. International Commission on Radiological Protection (ICRP). ICRP Publication 62: radiological protection in biomedical research. Ann ICRP. 1992;22.
15. Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamurthy N, et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225-34.
16. Tolvanen T, Lehtio K, Kulmala J, Oikonen V, Eskola O, Bergman J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674-80.
17. Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787-95.
18. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482-8.
19. Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, et al. (S)-4-(3-18F-Fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging - dosimetry. J Nucl Med. 2013;54:861-6.
20. Beauregard JM, Croteau E, Ahmed N, van Lier JE, Benard F. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F- fluoroestradiol using serial whole-body PET/CT. J Nucl Med. 2009;50:100-7.